Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • Lorlatinib had robust overall and intracranial (IC) activity against ALK+ advanced NSCLC after second-generation ALK TKIs. • Objective responses occurred independently of prior chemotherapy treatment. • Elevated IC versus extracranial ORR was observed, especially in patients with fewer treatment lines. • Competing risk analysis showed that probability of first event being CNS progression was lower than non-CNS progression.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.